GENFIT Stock Euronext Paris
Equities
FR0004163111
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 89.63M 96.47M | Sales 2025 * | 48.78M 52.51M | Capitalization | 161M 173M |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.14M | Net income 2025 * | -21M -22.6M | EV / Sales 2024 * | 1.49 x |
Net cash position 2024 * | 27.6M 29.71M | Net cash position 2025 * | 44.9M 48.33M | EV / Sales 2025 * | 2.38 x |
P/E ratio 2024 * |
6.88
x | P/E ratio 2025 * |
24.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.71% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 18-04-30 |
Founder | 68 | 99-08-31 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21-04-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 21-03-03 | |
Founder | 68 | 99-08-31 | |
Founder | 52 | 99-09-14 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |